Trial Outcomes & Findings for Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy. (NCT NCT04721821)

Results Overview

CDAI was a simplified index for assessing the disease activity comprising of the swollen joint counts (SJC), tender/painful joint counts (TJC), participant's global assessment of disease activity (PtGA) and physician's global assessment of disease activity (PGA). CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment range from 0 to 28, higher scores meant worse condition), PtGA and PGA (score range from 0 to 10, assessed on 0-10 centimeter (cm) visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0 (no disease) to 76 (severe disease), higher scores indicated worse condition. Achievement of LDA was defined by CDAI less than or equal to (\<=)10 in participants with moderate or high disease activity CDAI greater than (\>) 10 at baseline. Propensity score method was used for analysis of the outcome measure.

Recruitment status

COMPLETED

Target enrollment

7807 participants

Primary outcome timeframe

Month 6 visit post initiation of Tofacitinib or TNFis, during observation period from 06-November-2012 to 28-Feb-2021 (approximately 8.3 years); data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Results posted on

2024-04-12

Participant Flow

Data of participants diagnosed with rheumatoid arthritis (RA), enrolled in Corrona RA registry, initiated tofacitinib or tumor necrosis factor inhibitors (TNFis) on or after 06-November-2012, after failure with conventional synthetic disease modifying antirheumatic drugs (csDMARDs) treatment, were included.

Data was collected retrospectively for observation period from 06-November-2012 to 28-Feb-2021 (approximately 8.3 years). Data from eligible participants for aforesaid observation period were retrieved and observed in this retrospective study from 22-January-2021 to 29-November-2021 (approximately 10 months).

Participant milestones

Participant milestones
Measure	Tofacitinib (6-Month Follow-up) Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.	TNFis (6-Month Follow-up) Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.	Tofacitinib (12-Month Follow-up) Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	TNFis (12-Month Follow-up) Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.
Overall Study STARTED	989	3337	805	2676
Overall Study COMPLETED	989	3337	805	2676
Overall Study NOT COMPLETED	0	0	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

"Number Analyzed" refers to those participants whose data was available and is reported. Data for remaining participants was missing and not reported.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Tofacitinib (6-Month Follow-up) n=989 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.	TNFis (6-Month Follow-up) n=3337 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.	Tofacitinib (12-Month Follow-up) n=805 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	TNFis (12-Month Follow-up) n=2676 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Total n=7807 Participants Total of all reporting groups
Age, Continuous	60.5 Years STANDARD_DEVIATION 11.8 • n=987 Participants • "Number Analyzed" refers to those participants whose data was available and is reported. Data for remaining participants was missing and not reported.	58.4 Years STANDARD_DEVIATION 12.8 • n=3334 Participants • "Number Analyzed" refers to those participants whose data was available and is reported. Data for remaining participants was missing and not reported.	59.9 Years STANDARD_DEVIATION 11.9 • n=803 Participants • "Number Analyzed" refers to those participants whose data was available and is reported. Data for remaining participants was missing and not reported.	58.9 Years STANDARD_DEVIATION 12.6 • n=2671 Participants • "Number Analyzed" refers to those participants whose data was available and is reported. Data for remaining participants was missing and not reported.	59.0 Years STANDARD_DEVIATION 12.5 • n=7795 Participants • "Number Analyzed" refers to those participants whose data was available and is reported. Data for remaining participants was missing and not reported.
Sex: Female, Male Female	804 Participants n=987 Participants • "Number Analyzed" refers to those participants whose data was available and is reported. Data for remaining participants was missing and not reported.	2634 Participants n=3337 Participants • "Number Analyzed" refers to those participants whose data was available and is reported. Data for remaining participants was missing and not reported.	651 Participants n=803 Participants • "Number Analyzed" refers to those participants whose data was available and is reported. Data for remaining participants was missing and not reported.	2094 Participants n=2674 Participants • "Number Analyzed" refers to those participants whose data was available and is reported. Data for remaining participants was missing and not reported.	6183 Participants n=7801 Participants • "Number Analyzed" refers to those participants whose data was available and is reported. Data for remaining participants was missing and not reported.
Sex: Female, Male Male	183 Participants n=987 Participants • "Number Analyzed" refers to those participants whose data was available and is reported. Data for remaining participants was missing and not reported.	703 Participants n=3337 Participants • "Number Analyzed" refers to those participants whose data was available and is reported. Data for remaining participants was missing and not reported.	152 Participants n=803 Participants • "Number Analyzed" refers to those participants whose data was available and is reported. Data for remaining participants was missing and not reported.	580 Participants n=2674 Participants • "Number Analyzed" refers to those participants whose data was available and is reported. Data for remaining participants was missing and not reported.	1618 Participants n=7801 Participants • "Number Analyzed" refers to those participants whose data was available and is reported. Data for remaining participants was missing and not reported.
Race/Ethnicity, Customized White	846 Participants n=989 Participants	2,716 Participants n=3337 Participants	697 Participants n=805 Participants	2199 Participants n=2676 Participants	6458 Participants n=7807 Participants
Race/Ethnicity, Customized Hispanic	67 Participants n=989 Participants	272 Participants n=3337 Participants	53 Participants n=805 Participants	192 Participants n=2676 Participants	584 Participants n=7807 Participants
Race/Ethnicity, Customized Black	42 Participants n=989 Participants	212 Participants n=3337 Participants	30 Participants n=805 Participants	167 Participants n=2676 Participants	451 Participants n=7807 Participants
Race/Ethnicity, Customized Asian	6 Participants n=989 Participants	55 Participants n=3337 Participants	6 Participants n=805 Participants	40 Participants n=2676 Participants	107 Participants n=7807 Participants
Race/Ethnicity, Customized Other	13 Participants n=989 Participants	50 Participants n=3337 Participants	5 Participants n=805 Participants	44 Participants n=2676 Participants	112 Participants n=7807 Participants
Race/Ethnicity, Customized Missing	15 Participants n=989 Participants	32 Participants n=3337 Participants	14 Participants n=805 Participants	34 Participants n=2676 Participants	95 Participants n=7807 Participants

PRIMARY outcome

Timeframe: Month 6 visit post initiation of Tofacitinib or TNFis, during observation period from 06-November-2012 to 28-Feb-2021 (approximately 8.3 years); data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms and had moderate or high disease activity (CDAI\>10) at baseline.

CDAI was a simplified index for assessing the disease activity comprising of the swollen joint counts (SJC), tender/painful joint counts (TJC), participant's global assessment of disease activity (PtGA) and physician's global assessment of disease activity (PGA). CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment range from 0 to 28, higher scores meant worse condition), PtGA and PGA (score range from 0 to 10, assessed on 0-10 centimeter (cm) visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0 (no disease) to 76 (severe disease), higher scores indicated worse condition. Achievement of LDA was defined by CDAI less than or equal to (\<=)10 in participants with moderate or high disease activity CDAI greater than (\>) 10 at baseline. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=502 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=513 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved Low Disease Activity (LDA) Based on Clinical Disease Activity Index (CDAI) at Month 6: Tofacitinib Overall Versus TNFis Overall	—	—	129 Participants	140 Participants

PRIMARY outcome

Timeframe: Month 6 visit post initiation of Tofacitinib during observation period from 06-November-2012 to 28-Feb-2021 (approximately 8.3 years); data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms and had moderate or high disease activity CDAI \>10 at baseline.

CDAI was a simplified index for assessing the disease activity comprising of the SJC, TJC, PtGA and PGA. CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment, range from 0 to 28, higher scores meant worse condition), PtGA and PGA (score range from 0 to 10, assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0 (no disease) to 76 (severe disease), higher scores indicated worse condition. Achievement of LDA was defined by CDAI \<=10 in participants with moderate or high disease activity CDAI\>10 at baseline. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=228 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=231 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved LDA Based on CDAI at Month 6: Tofacitinib Monotherapy Versus Tofacitinib Combination Therapy	—	—	66 Participants	48 Participants

PRIMARY outcome

Timeframe: Month 6 visit post initiation of TNFis, during observation period from 06-November-2012 to 28-Feb-2021 (approximately 8.3 years); data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms and had moderate or high disease activity (CDAI\>10) at baseline.

CDAI was a simplified index for assessing the disease activity comprising of the SJC, TJC, PtGA and PGA. CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment, range from 0 to 28, higher scores meant worse condition), PtGA and PGA (score range from 0 to 10, assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0 (no disease) to 76 (severe disease), higher scores indicated worse condition. Achievement of LDA was defined by CDAI \<=10 in participants with moderate or high disease activity CDAI\>10 at baseline. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=469 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=438 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved LDA Based on CDAI at Month 6: TNFi Monotherapy Versus TNFis Combination Therapy	—	—	166 Participants	154 Participants

PRIMARY outcome

Timeframe: Month 6 visit post initiation of Tofacitinib or TNFis, during observation period from 06-November-2012 to 28-Feb-2021 (approximately 8.3 years); data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms and had moderate or high disease activity (CDAI\>10) at baseline.

CDAI was a simplified index for assessing the disease activity comprising of the SJC, TJC, PtGA and PGA. CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment, range from 0 to 28, higher scores meant worse condition), PtGA and PGA (score range from 0 to 10, assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0 (no disease) to 76 (severe disease), higher scores indicated worse condition. Achievement of LDA was defined by CDAI \<=10 in participants with moderate or high disease activity CDAI\>10 at baseline. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=223 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=222 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved LDA Based on CDAI at Month 6: Tofacitinib Monotherapy Versus TNFis Combination Therapy	—	—	59 Participants	68 Participants

PRIMARY outcome

Timeframe: Month 6 visit post initiation of Tofacitinib or TNFis, during observation period from 06-November-2012 to 28-Feb-2021 (approximately 8.3 years); data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms and had moderate or high disease activity (CDAI\>10) at baseline.

CDAI was a simplified index for assessing the disease activity comprising of the SJC, TJC, PtGA and PGA. CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment, range from 0 to 28, higher scores meant worse condition), PtGA and PGA (score range from 0 to 10, assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0 (no disease) to 76 (severe disease), higher scores indicated worse condition. Achievement of LDA was defined by CDAI \<=10 in participants with moderate or high disease activity CDAI\>10 at baseline. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=310 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=301 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved LDA Based on CDAI at Month 6: Tofacitinib Combination Therapy Versus TNFis Combination Therapy	—	—	82 Participants	82 Participants

PRIMARY outcome

Timeframe: Month 12 visit post initiation of Tofacitinib or TNFis, during observation period from 06-November-2012 to 28-Feb-2021 (approximately 8.3 years); data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms and had moderate or high disease activity (CDAI\>10) at baseline.

CDAI was a simplified index for assessing the disease activity comprising of the SJC, TJC, PtGA and PGA. CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment, range from 0 to 28, higher scores meant worse condition), PtGA and PGA (score range from 0 to 10, assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0 (no disease) to 76 (severe disease), higher scores indicated worse condition. Achievement of LDA was defined by CDAI \<=10 in participants with moderate or high disease activity CDAI\>10 at baseline. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=419 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=417 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved LDA Based on CDAI at Month 12: Tofacitinib Overall Versus TNFis Overall	—	—	104 Participants	127 Participants

PRIMARY outcome

Timeframe: Month 12 visit post initiation of Tofacitinib during observation period from 06-November-2012 to 28-Feb-2021 (approximately 8.3 years); data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms and had moderate or high disease activity (CDAI\>10) at baseline.

CDAI was a simplified index for assessing the disease activity comprising of the SJC, TJC, PtGA and PGA. CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment, range from 0 to 28, higher scores meant worse condition), PtGA and PGA (score range from 0 to 10, assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0 (no disease) to 76 (severe disease), higher scores indicated worse condition. Achievement of LDA was defined by CDAI \<=10 in participants with moderate or high disease activity CDAI\>10 at baseline. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=180 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=176 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved LDA Based on CDAI at Month 12: Tofacitinib Monotherapy Versus Tofacitinib Combination Therapy	—	—	44 Participants	48 Participants

PRIMARY outcome

Timeframe: Month 12 visit post initiation of TNFis, during observation period from 06-November-2012 to 28-Feb-2021 (approximately 8.3 years); data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms and had moderate or high disease activity (CDAI\>10) at baseline.

CDAI was a simplified index for assessing the disease activity comprising of the SJC, TJC, PtGA and PGA. CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment, range from 0 to 28, higher scores meant worse condition), PtGA and PGA (score range from 0 to 10, assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0 (no disease) to 76 (severe disease), higher scores indicated worse condition. Achievement of LDA was defined by CDAI \<=10 in participants with moderate or high disease activity CDAI\>10 at baseline. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=362 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=356 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved LDA Based on CDAI at Month 12: TNFis Monotherapy Versus TNFis Combination Therapy	—	—	123 Participants	129 Participants

PRIMARY outcome

Timeframe: Month 12 visit post initiation of Tofacitinib or TNFis, during observation period from 06-November-2012 to 28-Feb-2021 (approximately 8.3 years); data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms and had moderate or high disease activity (CDAI\>10) at baseline.

CDAI was a simplified index for assessing the disease activity comprising of the SJC, TJC, PtGA and PGA. CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment, range from 0 to 28, higher scores meant worse condition), PtGA and PGA (score range from 0 to 10, assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0 (no disease) to 76 (severe disease), higher scores indicated worse condition. Achievement of LDA was defined by CDAI \<=10 in participants with moderate or high disease activity CDAI\>10 at baseline. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=160 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=165 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved LDA Based on CDAI at Month 12: Tofacitinib Monotherapy Versus TNFis Combination Therapy	—	—	40 Participants	52 Participants

PRIMARY outcome

Timeframe: Month 12 visit post initiation of Tofacitinib or TNFis, during observation period from 06-November-2012 to 28-Feb-2021 (approximately 8.3 years); data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms and had moderate or high disease activity (CDAI\>10) at baseline.

CDAI was a simplified index for assessing the disease activity comprising of the SJC, TJC, PtGA and PGA. CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment, range from 0 to 28, higher scores meant worse condition), PtGA and PGA (score range from 0 to 10, assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0 (no disease) to 76 (severe disease), higher scores indicated worse condition. Achievement of LDA was defined by CDAI \<=10 in participants with moderate or high disease activity CDAI\>10 at baseline. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=234 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=240 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved LDA Based on CDAI at Month 12: Tofacitinib Combination Therapy Versus TNFis Combination Therapy	—	—	57 Participants	67 Participants

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms and had LDA, moderate or high disease activity (CDAI \>2.8) at baseline.

CDAI was a simplified index for assessing the disease activity comprising of the SJC, TJC, PtGA and PGA. CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment, range from 0 to 28, higher scores meant worse condition), PtGA and PGA (score range from 0 to 10, assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0 (no disease) to 76 (severe disease), higher scores indicated worse condition. Achievement of remission was defined by CDAI (\<=2.8) in those participants with LDA, moderate or high disease activity (CDAI \>2.8) at baseline. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=572 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=565 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=686 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=680 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved Remission Based on CDAI at Month 6 and 12: Tofacitinib Overall Versus TNFis Overall	53 Participants	61 Participants	61 Participants	71 Participants

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms and had LDA, moderate or high disease activity (CDAI \>2.8) at baseline.

CDAI was a simplified index for assessing the disease activity comprising of the SJC, TJC, PtGA and PGA. CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment, range from 0 to 28, higher scores meant worse condition), PtGA and PGA (score range from 0 to 10, assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0 (no disease) to 76 (severe disease), higher scores indicated worse condition. Achievement of remission was defined by CDAI (\<=2.8) in those participants with LDA, moderate or high disease activity (CDAI \>2.8) at baseline. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=259 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=251 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=317 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=311 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved Remission Based on CDAI at Month 6 and 12: Tofacitinib Monotherapy Versus Tofacitinib Combination Therapy	23 Participants	24 Participants	29 Participants	23 Participants

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of TNFis, during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms and had LDA, moderate or high disease activity (CDAI \>2.8) at baseline.

CDAI was a simplified index for assessing the disease activity comprising of the SJC, TJC, PtGA and PGA. CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment, range from 0 to 28, higher scores meant worse condition), PtGA and PGA (score range from 0 to 10, assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0 (no disease) to 76 (severe disease), higher scores indicated worse condition. Achievement of remission was defined by CDAI (\<=2.8) in those participants with LDA, moderate or high disease activity (CDAI \>2.8) at baseline. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=474 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=485 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=606 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=604 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved Remission Based on CDAI at Month 6 and 12: TNFis Monotherapy Versus TNFis Combination Therapy	55 Participants	56 Participants	69 Participants	78 Participants

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms and had LDA, moderate or high disease activity (CDAI \>2.8) at baseline.

CDAI was a simplified index for assessing the disease activity comprising of the SJC, TJC, PtGA and PGA. CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment, range from 0 to 28, higher scores meant worse condition), PtGA and PGA (score range from 0 to 10, assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0 (no disease) to 76 (severe disease), higher scores indicated worse condition. Achievement of remission was defined by CDAI (\<=2.8) in those participants with LDA, moderate or high disease activity (CDAI \>2.8) at baseline. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=230 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=236 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=315 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=316 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved Remission Based on CDAI at Month 6 and 12: Tofacitinib Monotherapy Versus TNFis Combination Therapy	20 Participants	30 Participants	28 Participants	36 Participants

SECONDARY outcome

Timeframe: Month 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis, during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms and had LDA, moderate or high disease activity (CDAI \>2.8) at baseline.

CDAI was a simplified index for assessing the disease activity comprising of the SJC, TJC, PtGA and PGA. CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment, range from 0 to 28, higher scores meant worse condition), PtGA and PGA (score range from 0 to 10, assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0 (no disease) to 76 (severe disease), higher scores indicated worse condition. Achievement of remission was defined by CDAI (\<=2.8) in those participants with LDA, moderate or high disease activity (CDAI \>2.8) at baseline. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=319 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=317 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=414 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=412 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved Remission Based on CDAI at Month 6 and 12: Tofacitinib Combination Therapy Versus TNFis Combination Therapy	26 Participants	23 Participants	34 Participants	41 Participants

SECONDARY outcome

Timeframe: Baseline, Months 6 and 12 visit (for respective arms) post initiation of Tofacitinib or TNFis, during observation period from 06-Nov-2012 to 28-Feb-2021 (approximately 8.3 years);data collected and studied from 22-Jan-2021 to 29-Nov-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

CDAI was a simplified index for assessing the disease activity comprising of the SJC, TJC, PtGA and PGA. CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment, range from 0 to 28, higher scores meant worse condition), PtGA and PGA (score range from 0 to 10, assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0 (no disease) to 76 (severe disease), higher scores indicated worse condition. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=611 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=611 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=735 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=735 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Change From Baseline in CDAI 0-76 at Month 6 and 12: Tofacitinib Overall Versus TNFis Overall	-3.29 Units on a scale Standard Deviation 13.28	-4.39 Units on a scale Standard Deviation 11.82	-3.85 Units on a scale Standard Deviation 12.71	-3.98 Units on a scale Standard Deviation 12.64

SECONDARY outcome

Timeframe: Baseline,Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

CDAI was a simplified index for assessing the disease activity comprising of the SJC, TJC, PtGA and PGA. CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment, range from 0 to 28, higher scores meant worse condition), PtGA and PGA (score range from 0 to 10, assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0 (no disease) to 76 (severe disease), higher scores indicated worse condition. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=277 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=277 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=345 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=345 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Change From Baseline in CDAI 0-76 at Month 6 and 12: Tofacitinib Monotherapy Versus Tofacitinib Combination Therapy	-3.30 Units on a scale Standard Deviation 13.68	-2.31 Units on a scale Standard Deviation 12.23	-3.43 Units on a scale Standard Deviation 12.77	-2.66 Units on a scale Standard Deviation 12.59

SECONDARY outcome

Timeframe: Baseline, Months 6 and 12 visit(for respective arms)post initiation of TNFis, during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

CDAI was a simplified index for assessing the disease activity comprising of the SJC, TJC, PtGA and PGA. CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment, range from 0 to 28, higher scores meant worse condition), PtGA and PGA (score range from 0 to 10, assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0 (no disease) to 76 (severe disease), higher scores indicated worse condition. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=536 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=536 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=670 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=670 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Change From Baseline in CDAI 0-76 at Month 6 and 12: TNFis Monotherapy Versus TNFis Combination Therapy	-5.07 Units on a scale Standard Deviation 12.08	-3.49 Units on a scale Standard Deviation 11.76	-4.39 Units on a scale Standard Deviation 12.32	-4.36 Units on a scale Standard Deviation 11.82

SECONDARY outcome

Timeframe: Baseline, Months 6 and 12 visit (for respective arms) post initiation of Tofacitinib or TNFis, during observation period from 06-Nov-2012 to 28-Feb-2021 (approximately 8.3 years);data collected and studied from 22-Jan-2021 to 29-Nov-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

CDAI was a simplified index for assessing the disease activity comprising of the SJC, TJC, PtGA and PGA. CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment, range from 0 to 28, higher scores meant worse condition), PtGA and PGA (score range from 0 to 10, assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0 (no disease) to 76 (severe disease), higher scores indicated worse condition. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=246 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=246 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=343 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=343 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Change From Baseline in CDAI 0-76 at Month 6 and 12: Tofacitinib Monotherapy vs TNFis Combination Therapy	-3.33 Units on a scale Standard Deviation 13.51	-4.39 Units on a scale Standard Deviation 10.85	-3.26 Units on a scale Standard Deviation 12.68	-3.66 Units on a scale Standard Deviation 12.41

SECONDARY outcome

Timeframe: Baseline, Months 6 and 12 visit (for respective arms) post initiation of Tofacitinib or TNFis, during observation period from 06-Nov-2012 to 28-Feb-2021 (approximately 8.3 years);data collected and studied from 22-Jan-2021 to 29-Nov-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

CDAI was a simplified index for assessing the disease activity comprising of the SJC, TJC, PtGA and PGA. CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment, range from 0 to 28, higher scores meant worse condition), PtGA and PGA (score range from 0 to 10, assessed on 0-10 cm visual analog scale; higher scores indicated greater affection due to disease activity). CDAI total score = 0 (no disease) to 76 (severe disease), higher scores indicated worse condition. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=344 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=344 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=443 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=443 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Change From Baseline in CDAI 0-76 at Month 6 and 12: Tofacitinib Combination Therapy vs TNFis Combination Therapy	-3.28 Units on a scale Standard Deviation 12.59	-4.29 Units on a scale Standard Deviation 12.23	-3.92 Units on a scale Standard Deviation 13.20	-4.53 Units on a scale Standard Deviation 11.94

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

mACR 20/50/70 response was defined as response greater than or equal to( \>=) 20 percent (%), 50%, or 70% improvement in tender and swollen joint count and 20%, 50% or 70% improvement respectively in 2 of the following 4 criteria: 1) participant assessment of pain (scored from 0 to 100, higher scores indicated worsening of pain); 2) participant global assessment of disease activity (scored from 0 to 100, higher scores indicated worsening of condition); 3) physician global assessment of disease activity (scored from 0 to 100, higher scores indicated worsening of condition); 4) self-assessed disability index of the modified Health Assessment Questionnaire (mHAQ) \[scored from 0 to 3, higher scores indicated worsening of function\]. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=608 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=602 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=731 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=730 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants With Modified American College of Rheumatology (mACR) 20/50/70 at Month 6 and 12: Tofacitinib Overall Versus TNFis Overall mACR 20	114 Participants	109 Participants	138 Participants	143 Participants
Number of Participants With Modified American College of Rheumatology (mACR) 20/50/70 at Month 6 and 12: Tofacitinib Overall Versus TNFis Overall mACR 50	52 Participants	63 Participants	73 Participants	87 Participants
Number of Participants With Modified American College of Rheumatology (mACR) 20/50/70 at Month 6 and 12: Tofacitinib Overall Versus TNFis Overall mACR 70	22 Participants	33 Participants	33 Participants	32 Participants

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

mACR 20/50/70 response was defined as response \>= 20%, 50%, or 70% improvement in tender and swollen joint count and 20%, 50% or 70% improvement respectively in 2 of the following 4 criteria: 1) participant assessment of pain (scored from 0 to 100, higher scores indicated worsening of pain); 2) participant global assessment of disease activity (scored from 0 to 100, higher scores indicated worsening of condition); 3) physician global assessment of disease activity (scored from 0 to 100, higher scores indicated worsening of condition); 4) self-assessed disability index of the mHAQ (scored from 0 to 3, higher scores indicated worsening of function). Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=272 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=267 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=333 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=328 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants With MACR 20/50/70 at Month 6 and 12: Tofacitinib Monotherapy Versus Tofacitinib Combination Therapy mACR 20	46 Participants	43 Participants	63 Participants	56 Participants
Number of Participants With MACR 20/50/70 at Month 6 and 12: Tofacitinib Monotherapy Versus Tofacitinib Combination Therapy mACR 50	20 Participants	19 Participants	38 Participants	25 Participants
Number of Participants With MACR 20/50/70 at Month 6 and 12: Tofacitinib Monotherapy Versus Tofacitinib Combination Therapy mACR 70	12 Participants	8 Participants	15 Participants	10 Participants

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of TNFis, during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

mACR 20/50/70 response was defined as response \>= 20%, 50%, or 70% improvement in tender and swollen joint count and 20%, 50% or 70% improvement respectively in 2 of the following 4 criteria: 1) participant assessment of pain (scored from 0 to 100, higher scores indicated worsening of pain); 2) participant global assessment of disease activity (scored from 0 to 100, higher scores indicated worsening of condition); 3) physician global assessment of disease activity (scored from 0 to 100, higher scores indicated worsening of condition); 4) self-assessed disability index of the mHAQ (scored from 0 to 3, higher scores indicated worsening of function). Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=531 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=533 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=666 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=663 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants With MACR 20/50/70 at Month 6 and 12: TNFis Monotherapy Versus TNFis Combination Therapy mACR 20	111 Participants	107 Participants	137 Participants	151 Participants
Number of Participants With MACR 20/50/70 at Month 6 and 12: TNFis Monotherapy Versus TNFis Combination Therapy mACR 50	59 Participants	59 Participants	90 Participants	85 Participants
Number of Participants With MACR 20/50/70 at Month 6 and 12: TNFis Monotherapy Versus TNFis Combination Therapy mACR 70	34 Participants	26 Participants	47 Participants	35 Participants

SECONDARY outcome

Timeframe: Month 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis, during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

mACR 20/50/70 response was defined as response \>= 20%, 50%, or 70% improvement in tender and swollen joint count and 20%, 50% or 70% improvement respectively in 2 of the following 4 criteria: 1) participant assessment of pain (scored from 0 to 100, higher scores indicated worsening of pain); 2) participant global assessment of disease activity (scored from 0 to 100, higher scores indicated worsening of condition); 3) physician global assessment of disease activity (scored from 0 to 100, higher scores indicated worsening of condition); 4) self-assessed disability index of the mHAQ (scored from 0 to 3, higher scores indicated worsening of function). Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=244 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=244 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=338 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=340 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants With MACR 20/50/70 at Month 6 and 12: Tofacitinib Monotherapy Versus TNFis Combination Therapy mACR 20	42 Participants	33 Participants	66 Participants	66 Participants
Number of Participants With MACR 20/50/70 at Month 6 and 12: Tofacitinib Monotherapy Versus TNFis Combination Therapy mACR 50	21 Participants	19 Participants	36 Participants	37 Participants
Number of Participants With MACR 20/50/70 at Month 6 and 12: Tofacitinib Monotherapy Versus TNFis Combination Therapy mACR 70	12 Participants	9 Participants	13 Participants	12 Participants

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

mACR 20/50/70 response was defined as response \>= 20%, 50%, or 70% improvement in tender and swollen joint count and 20%, 50% or 70% improvement respectively in 2 of the following 4 criteria: 1) participant assessment of pain (scored from 0 to 100, higher scores indicated worsening of pain); 2) participant global assessment of disease activity (scored from 0 to 100, higher scores indicated worsening of condition); 3) physician global assessment of disease activity (scored from 0 to 100, higher scores indicated worsening of condition); 4) self-assessed disability index of the mHAQ (scored from 0 to 3, higher scores indicated worsening of function). Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=343 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=341 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=442 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=439 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants With MACR 20/50/70 at Month 6 and 12: Tofacitinib Combination Therapy Versus TNFis Combination Therapy mACR 20	65 Participants	57 Participants	91 Participants	91 Participants
Number of Participants With MACR 20/50/70 at Month 6 and 12: Tofacitinib Combination Therapy Versus TNFis Combination Therapy mACR 50	30 Participants	32 Participants	47 Participants	39 Participants
Number of Participants With MACR 20/50/70 at Month 6 and 12: Tofacitinib Combination Therapy Versus TNFis Combination Therapy mACR 70	10 Participants	14 Participants	24 Participants	16 Participants

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms and DAS28 ESR \>3.2 at baseline.

DAS28 ESR was calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, ESR (millimeters per hour \[mm/hour\]) and participant's global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated high disease activity). DAS 28 ESR =0.56\*sqrt (PJC28) + 0.28\*sqrt (SJC28) + 0.70\*In (ESR) + 0.014\*PtGA; ln = natural logarithm, sqrt = square root of. DAS28 ESR \<= 3.2 = low disease activity, DAS28 ESR \> 3.2 and \<=5.1 = moderate and \>5.1 = high disease activity. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=265 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=232 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=314 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=279 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved LDA Based on Disease Activity Score (DAS 28) Erythrocyte Sedimentation Rate (ESR) at Month 6 and 12: Tofacitinib Overall Versus TNFis Overall	44 Participants	40 Participants	54 Participants	64 Participants

SECONDARY outcome

Timeframe: Months 6 and 12 visit (for respective arms)post initiation of Tofacitinib during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms and DAS28 ESR \>3.2 at baseline.

DAS28 ESR was calculated from the number of SJC and PJC using the 28 joints count, ESR (mm/hour) and PGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated high disease activity). DAS 28 ESR =0.56\*sqrt (PJC28) + 0.28\*sqrt (SJC28) + 0.70\*In (ESR) + 0.014\*PtGA; ln = natural logarithm, sqrt = square root of. DAS28 ESR \<= 3.2 = low disease activity, DAS28 ESR \> 3.2 and \<=5.1 = moderate and \>5.1 = high disease activity. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=112 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=108 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=131 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=149 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved LDA Based on DAS 28 ESR at Month 6 and 12: Tofacitinib Monotherapy Versus Tofacitinib Combination Therapy	14 Participants	16 Participants	24 Participants	20 Participants

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of TNFis, during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms and DAS28 ESR \>3.2 at baseline.

DAS28 ESR was calculated from the number of SJC and PJC using the 28 joints count, ESR (mm/hour) and PGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated high disease activity). DAS 28 ESR =0.56\*sqrt (PJC28) + 0.28\*sqrt (SJC28) + 0.70\*In (ESR) + 0.014\*PtGA; ln = natural logarithm, sqrt = square root of. DAS28 ESR \<= 3.2 = low disease activity, DAS28 ESR \> 3.2 and \<=5.1 = moderate and \>5.1 = high disease activity. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=204 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=205 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=255 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=236 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved LDA Based on DAS 28 ESR at Month 6 and 12: TNFis Monotherapy Versus TNFis Combination Therapy	39 Participants	45 Participants	62 Participants	56 Participants

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms and DAS28 ESR \>3.2 at baseline.

DAS28 ESR was calculated from the number of SJC and PJC using the 28 joints count, ESR (mm/hour) and PGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated high disease activity). DAS 28 ESR =0.56\*sqrt (PJC28) + 0.28\*sqrt (SJC28) + 0.70\*In (ESR) + 0.014\*PtGA; ln = natural logarithm, sqrt = square root of. DAS28 ESR \<= 3.2 = low disease activity, DAS28 ESR \> 3.2 and \<=5.1 = moderate and \>5.1 = high disease activity. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=95 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=88 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=129 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=129 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved LDA Based on DAS 28 ESR at Month 6 and 12: Tofacitinib Monotherapy Versus TNFis Combination Therapy	12 Participants	17 Participants	23 Participants	32 Participants

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms and DAS28 ESR \>3.2 at baseline.

DAS28 ESR was calculated from the number of SJC and PJC using the 28 joints count, ESR (mm/hour) and PGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated high disease activity). DAS 28 ESR =0.56\*sqrt (PJC28) + 0.28\*sqrt (SJC28) + 0.70\*In (ESR) + 0.014\*PtGA; ln = natural logarithm, sqrt = square root of. DAS28 ESR \<= 3.2 = low disease activity, DAS28 ESR \> 3.2 and \<=5.1 = moderate and \>5.1 = high disease activity. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=151 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=143 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=201 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=167 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved LDA Based on DAS 28 ESR at Month 6 and 12: Tofacitinib Combination Therapy vs TNFis Combination Therapy	24 Participants	24 Participants	36 Participants	34 Participants

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

HAQ: self-reported, valid assessment of functional disability in RA. The 20-question instrument assessed ability of participants to perform daily activities in 8 functional areas: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities. Eight items were rated on a 4-point Likert scale from 0 to 3, where 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranged from 0 to 3, where 0 = least difficulty and 3 = extreme difficulty, higher scores indicating worse functioning. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=611 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=611 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=735 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=735 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Health Assessment Questionnaire (HAQ) Score at Month 6 and 12: Tofacitinib Overall Versus TNFis Overall	0.98 Units on a scale Standard Deviation 0.73	1.05 Units on a scale Standard Deviation 0.74	1.02 Units on a scale Standard Deviation 0.71	1.06 Units on a scale Standard Deviation 0.71

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

HAQ: self-reported, valid assessment of functional disability in RA. The 20-question instrument assessed ability of participants to perform daily activities in 8 functional areas: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities. Eight items were rated on a 4-point Likert scale from 0 to 3, where 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranged from 0 to 3, where 0 = least difficulty and 3 = extreme difficulty, higher scores indicating worse functioning. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=277 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=277 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=345 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=345 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
HAQ Score at Month 6 and 12: Tofacitinib Monotherapy Versus Tofacitinib Combination Therapy	1.06 Units on a scale Standard Deviation 0.74	1.04 Units on a scale Standard Deviation 0.75	1.05 Units on a scale Standard Deviation 0.72	1.10 Units on a scale Standard Deviation 0.70

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of TNFis, during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

HAQ: self-reported, valid assessment of functional disability in RA. The 20-question instrument assessed ability of participants to perform daily activities in 8 functional areas: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities. Eight items were rated on a 4-point Likert scale from 0 to 3, where 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranged from 0 to 3, where 0 = least difficulty and 3 = extreme difficulty, higher scores indicating worse functioning. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=536 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=536 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=670 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=670 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
HAQ Score at Month 6 and 12: TNFi Monotherapy Versus TNFi Combination Therapy	0.95 Units on a scale Standard Deviation 0.71	0.98 Units on a scale Standard Deviation 0.73	0.92 Units on a scale Standard Deviation 0.71	0.88 Units on a scale Standard Deviation 0.70

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

HAQ: self-reported, valid assessment of functional disability in RA. The 20-question instrument assessed ability of participants to perform daily activities in 8 functional areas: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities. Eight items were rated on a 4-point Likert scale from 0 to 3, where 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranged from 0 to 3, where 0 = least difficulty and 3 = extreme difficulty, higher scores indicating worse functioning. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=246 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=246 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=343 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=343 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
HAQ Score at Month 6 and 12: Tofacitinib Monotherapy Versus TNFi Combination Therapy	1.01 Units on a scale Standard Deviation 0.72	0.99 Units on a scale Standard Deviation 0.73	0.98 Units on a scale Standard Deviation 0.69	1.00 Units on a scale Standard Deviation 0.67

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

HAQ: self-reported, valid assessment of functional disability in RA. The 20-question instrument assessed ability of participants to perform daily activities in 8 functional areas: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities. Eight items were rated on a 4-point Likert scale from 0 to 3, where 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranged from 0 to 3, where 0 = least difficulty and 3 = extreme difficulty, higher scores indicating worse functioning. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=344 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=344 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=443 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=443 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
HAQ Score at Month 6 and 12: Tofacitinib Combination Therapy Versus TNFi Combination Therapy	0.99 Units on a scale Standard Deviation 0.75	1.04 Units on a scale Standard Deviation 0.76	1.04 Units on a scale Standard Deviation 0.70	1.10 Units on a scale Standard Deviation 0.73

SECONDARY outcome

Timeframe: Months 6 and 12 visit (for respective arms) post initiation of Tofacitinib or TNFis, during observation period from 06-Nov-2012 to 28-Feb-2021 (approximately 8.3 years);data collected and studied from 22-Jan-2021 to 29-Nov-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

MCID improvement assessed based on HAQ. HAQ: self-reported, valid assessment of functional disability in RA. Assessed based on ability of participants to perform daily activities in 8 categories: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities. Eight items were rated on a 4-point Likert scale from 0 to 3, where 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranged from 0 to 3, where 0 = least difficulty and 3 = extreme difficulty, higher scores indicating worse functioning. Achievement of MCID for the HAQ was defined as decrease in minimum of 0.22 units from baseline. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=507 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=504 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=614 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=618 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved Minimally Clinically Important Difference (MCID) at Month 6 and 12: Tofacitinib Overall Versus TNFi Overall	174 Participants	135 Participants	197 Participants	213 Participants

SECONDARY outcome

Timeframe: Months 6 and 12 visit (for respective arms) post initiation of Tofacitinib during observation period from 06-Nov-2012 to 28-Feb-2021 (approximately 8.3 years);data collected and studied from 22-Jan-2021 to 29-Nov-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

MCID improvement assessed based on HAQ. HAQ: self-reported, valid assessment of functional disability in RA. Assessed based on ability of participants to perform daily activities in 8 categories: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities. Eight items were rated on a 4-point Likert scale from 0 to 3, where 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranged from 0 to 3, where 0 = least difficulty and 3 = extreme difficulty, higher scores indicating worse functioning. Achievement of MCID for the HAQ was defined as decrease in minimum of 0.22 units from baseline. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=226 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=221 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=269 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=278 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved MCID at Month 6 and 12: Tofacitinib Monotherapy Versus Tofacitinib Combination Therapy	73 Participants	75 Participants	94 Participants	82 Participants

SECONDARY outcome

Timeframe: Baseline, Months 6 and 12 visit (for respective arms) post initiation of TNFis, during observation period from 06-Nov-2012 to 28-Feb-2021 (approximately 8.3 years);data collected and studied from 22-Jan-2021 to 29-Nov-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

MCID improvement assessed based on HAQ. HAQ: self-reported, valid assessment of functional disability in RA. Assessed based on ability of participants to perform daily activities in 8 categories: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities. Eight items were rated on a 4-point Likert scale from 0 to 3, where 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranged from 0 to 3, where 0 = least difficulty and 3 = extreme difficulty, higher scores indicating worse functioning. Achievement of MCID for the HAQ was defined as decrease in minimum of 0.22 units from baseline. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=429 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=452 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=543 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=539 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved MCID at Month 6 and 12: TNFi Monotherapy Versus TNFi Combination Therapy	129 Participants	143 Participants	202 Participants	197 Participants

SECONDARY outcome

Timeframe: Months 6 and 12 visit (for respective arms) post initiation of Tofacitinib or TNFis, during observation period from 06-Nov-2012 to 28-Feb-2021 (approximately 8.3 years);data collected and studied from 22-Jan-2021 to 29-Nov-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

MCID improvement assessed based on HAQ. HAQ: self-reported, valid assessment of functional disability in RA. Assessed based on ability of participants to perform daily activities in 8 categories: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities. Eight items were rated on a 4-point Likert scale from 0 to 3, where 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranged from 0 to 3, where 0 = least difficulty and 3 = extreme difficulty, higher scores indicating worse functioning. Achievement of MCID for the HAQ was defined as decrease in minimum of 0.22 units from baseline. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=199 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=201 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=269 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=286 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved MCID at Month 6 and 12: Tofacitinib Monotherapy vs TNFi Combination Therapy	62 Participants	62 Participants	97 Participants	95 Participants

SECONDARY outcome

Timeframe: Months 6 and 12 visit (for respective arms) post initiation of Tofacitinib or TNFis, during observation period from 06-Nov-2012 to 28-Feb-2021 (approximately 8.3 years);data collected and studied from 22-Jan-2021 to 29-Nov-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

MCID improvement assessed based on HAQ. HAQ: self-reported, valid assessment of functional disability in RA. Assessed based on ability of participants to perform daily activities in 8 categories: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities. Eight items were rated on a 4-point Likert scale from 0 to 3, where 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranged from 0 to 3, where 0 = least difficulty and 3 = extreme difficulty, higher scores indicating worse functioning. Achievement of MCID for the HAQ was defined as decrease in minimum of 0.22 units from baseline. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=290 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=281 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=379 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=381 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Achieved MCID at Month 6 and 12: Tofacitinib Combination Therapy vs TNFi Combination Therapy	94 Participants	86 Participants	121 Participants	131 Participants

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

mHAQ is the modified version of HAQ which simplifies it from 20 questions to 8 questions, which assessed the ability to perform tasks due to rheumatoid arthritis. It comprised of 8 questions on 8 categories of daily living activities: dress/groom; arise; eat; grip; walk; hygiene; reach; and common activities over past week before specified time point. Eight items were rated on a 4-point Likert scale from 0 to 3, where 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranged from 0 to 3, where 0 = least difficulty and 3 = extreme difficulty, higher scores indicating worse functioning. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=611 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=611 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=735 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=735 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Modified Health Assessment Questionnaire (mHAQ) Score at Month 6 and 12: Tofacitinib Overall Versus TNFi Overall	0.52 Units on a scale Standard Deviation 0.54	0.53 Units on a scale Standard Deviation 0.51	0.51 Units on a scale Standard Deviation 0.50	0.53 Units on a scale Standard Deviation 0.51

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

mHAQ is the modified version of HAQ which simplifies it from 20 questions to 8 questions, which assessed the ability to perform tasks due to rheumatoid arthritis. It comprised of 8 questions on 8 categories of daily living activities: dress/groom; arise; eat; grip; walk; hygiene; reach; and common activities over past week before specified time point. Eight items were rated on a 4-point Likert scale from 0 to 3, where 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranged from 0 to 3, where 0 = least difficulty and 3 = extreme difficulty, higher scores indicating worse functioning. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=277 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=277 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=345 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=345 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
mHAQ Score at Month 6 and 12: Tofacitinib Monotherapy Versus Tofacitinib Combination Therapy	0.57 Units on a scale Standard Deviation 0.55	0.55 Units on a scale Standard Deviation 0.52	0.55 Units on a scale Standard Deviation 0.52	0.56 Units on a scale Standard Deviation 0.50

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of TNFis, during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

mHAQ is the modified version of HAQ which simplifies it from 20 questions to 8 questions, which assessed the ability to perform tasks due to rheumatoid arthritis. It comprised of 8 questions on 8 categories of daily living activities: dress/groom; arise; eat; grip; walk; hygiene; reach; and common activities over past week before specified time point. Eight items were rated on a 4-point Likert scale from 0 to 3, where 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranged from 0 to 3, where 0 = least difficulty and 3 = extreme difficulty, higher scores indicating worse functioning. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=536 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=536 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=670 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=670 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
mHAQ Score at Month 6 and 12: TNFi Monotherapy Versus TNFi Combination Therapy	0.48 Units on a scale Standard Deviation 0.47	0.49 Units on a scale Standard Deviation 0.51	0.48 Units on a scale Standard Deviation 0.48	0.44 Units on a scale Standard Deviation 0.47

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

mHAQ is the modified version of HAQ which simplifies it from 20 questions to 8 questions, which assessed the ability to perform tasks due to rheumatoid arthritis. It comprised of 8 questions on 8 categories of daily living activities: dress/groom; arise; eat; grip; walk; hygiene; reach; and common activities over past week before specified time point. Eight items were rated on a 4-point Likert scale from 0 to 3, where 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranged from 0 to 3, where 0 = least difficulty and 3 = extreme difficulty, higher scores indicating worse functioning. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=246 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=246 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=343 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=343 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
mHAQ Score at Month 6 and 12: Tofacitinib Monotherapy Versus TNFi Combination Therapy	0.53 Units on a scale Standard Deviation 0.52	0.49 Units on a scale Standard Deviation 0.50	0.50 Units on a scale Standard Deviation 0.48	0.50 Units on a scale Standard Deviation 0.50

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

mHAQ is the modified version of HAQ which simplifies it from 20 questions to 8 questions, which assessed the ability to perform tasks due to rheumatoid arthritis. It comprised of 8 questions on 8 categories of daily living activities: dress/groom; arise; eat; grip; walk; hygiene; reach; and common activities over past week before specified time point. Eight items were rated on a 4-point Likert scale from 0 to 3, where 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranged from 0 to 3, where 0 = least difficulty and 3 = extreme difficulty, higher scores indicating worse functioning. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=344 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=344 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=443 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=443 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
mHAQ Score at Month 6 and 12: Tofacitinib Combination Therapy Versus TNFi Combination Therapy	0.51 Units on a scale Standard Deviation 0.54	0.53 Units on a scale Standard Deviation 0.53	0.51 Units on a scale Standard Deviation 0.49	0.56 Units on a scale Standard Deviation 0.54

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

Pain VAS was assessed using 100 millimeter (mm) horizontal line to rate pain. Score ranged from 0 mm to 100 mm; where, 0 = no pain and 100 = worst possible pain. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=611 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=611 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=735 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=735 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Pain Visual Analog Scale (VAS) at Month 6 and 12: Tofacitinib Overall Versus TNFi Overall	43.22 Millimeter Standard Deviation 29.02	43.45 Millimeter Standard Deviation 29.22	43.61 Millimeter Standard Deviation 29.07	44.33 Millimeter Standard Deviation 28.80

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

Pain VAS was assessed using 100 mm horizontal line to rate pain. Score ranged from 0 mm to 100 mm; where, 0 = no pain and 100 = worst possible pain. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=277 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=277 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=345 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=345 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Pain VAS at Month 6 and 12: Tofacitinib Monotherapy Versus Tofacitinib Combination Therapy	46.91 Millimeter Standard Deviation 28.38	44.21 Millimeter Standard Deviation 28.90	43.99 Millimeter Standard Deviation 29.28	44.89 Millimeter Standard Deviation 28.54

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of TNFis, during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

Pain VAS was assessed using 100 mm horizontal line to rate pain. Score ranged from 0 mm to 100 mm; where, 0 = no pain and 100 = worst possible pain. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=536 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=536 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=670 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=670 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Pain VAS at Month 6 and 12: TNFi Monotherapy Versus TNFi Combination Therapy	42.74 Millimeter Standard Deviation 28.97	42.87 Millimeter Standard Deviation 29.33	42.70 Millimeter Standard Deviation 29.43	41.80 Millimeter Standard Deviation 28.60

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

Pain VAS was assessed using 100 mm horizontal line to rate pain. Score ranged from 0 mm to 100 mm; where, 0 = no pain and 100 = worst possible pain. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=246 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=246 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=343 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=343 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Pain VAS at Month 6 and 12: Tofacitinib Monotherapy Versus TNFi Combination Therapy	46.11 Millimeter Standard Deviation 28.41	41.82 Millimeter Standard Deviation 28.53	43.56 Millimeter Standard Deviation 29.23	42.97 Millimeter Standard Deviation 27.64

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

Pain VAS was assessed using 100 mm horizontal line to rate pain. Score ranged from 0 mm to 100 mm; where, 0 = no pain and 100 = worst possible pain. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=443 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=443 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=443 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=443 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Pain VAS at Month 6 and 12: Tofacitinib Combination Therapy vs TNFi Combination Therapy	43.13 Millimeter Standard Deviation 29.48	44.62 Millimeter Standard Deviation 29.08	43.62 Millimeter Standard Deviation 28.79	44.30 Millimeter Standard Deviation 28.80

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

Pain VAS was assessed using 100 mm horizontal line to rate pain. Score ranged from 0 mm to 100 mm; where, 0 = no pain and 100 = worst possible pain. Participants who reported VAS \<= 20 mm were categorized with mild pain and were reported in this outcome measure. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=472 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=476 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=564 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=586 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Experienced Mild Pain at Month 6 and 12: Tofacitinib Overall Versus TNFi Overall	79 Participants	79 Participants	98 Participants	102 Participants

SECONDARY outcome

Timeframe: Months 6 and 12 visit (for respective arms)post initiation of Tofacitinib during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

Pain VAS was assessed using 100 mm horizontal line to rate pain. Score ranged from 0 mm to 100 mm; where, 0 = no pain and 100 = worst possible pain. Participants who reported VAS \<= 20 mm were categorized with mild pain and were reported in this outcome measure. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=214 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=209 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=261 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=265 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Experienced Mild Pain at Month 6 and 12: Tofacitinib Monotherapy Versus Tofacitinib Combination Therapy	30 Participants	27 Participants	43 Participants	42 Participants

SECONDARY outcome

Timeframe: Months 6 and 12 visit (for respective arms) post initiation of TNFis, during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years); data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

Pain VAS was assessed using 100 mm horizontal line to rate pain. Score ranged from 0 mm to 100 mm; where, 0 = no pain and 100 = worst possible pain. Participants who reported VAS \<= 20 mm were categorized with mild pain and were reported in this outcome measure. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=409 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=428 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=524 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=520 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Experienced Mild Pain at Month 6 and 12: TNFi Monotherapy Versus TNFi Combination Therapy	73 Participants	71 Participants	107 Participants	96 Participants

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

Pain VAS was assessed using 100 mm horizontal line to rate pain. Score ranged from 0 mm to 100 mm; where, 0 = no pain and 100 = worst possible pain. Participants who reported VAS \<= 20 mm were categorized with mild pain and were reported in this outcome measure. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=186 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=191 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=256 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=258 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Experienced Mild Pain at Month 6 and 12: Tofacitinib Monotherapy Versus TNFi Combination Therapy	28 Participants	25 Participants	44 Participants	40 Participants

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

Pain VAS was assessed using 100 mm horizontal line to rate pain. Score ranged from 0 mm to 100 mm; where, 0 = no pain and 100 = worst possible pain. Participants who reported VAS \<= 20 mm were categorized with mild pain and were reported in this outcome measure. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=265 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=265 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=348 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=348 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Number of Participants Who Experienced Mild Pain at Month 6 and 12: Tofacitinib Combination Therapy Versus TNFi Combination Therapy	39 Participants	36 Participants	62 Participants	56 Participants

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

Participants assessed their fatigue using a 0 to 100 mm VAS scale, where 0 mm = no fatigue and 100 mm = worst possible fatigue. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=611 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=611 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=735 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=735 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Fatigue VAS at Month 6 and 12: Tofacitinib Overall Versus TNFi Overall	46.75 Millimeter Standard Deviation 30.71	46.93 Millimeter Standard Deviation 29.83	46.23 Millimeter Standard Deviation 29.42	48.52 Millimeter Standard Deviation 30.19

SECONDARY outcome

Timeframe: Months 6 and 12 visit (for respective arms) post initiation of Tofacitinib during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years); data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

Participants assessed their fatigue using a 0 to 100 mm VAS scale, where 0 mm = no fatigue and 100 mm = worst possible fatigue. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=277 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=277 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=345 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=345 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Fatigue VAS at Month 6 and 12: Tofacitinib Monotherapy Versus Tofacitinib Combination Therapy	48.51 Millimeter Standard Deviation 29.97	48.64 Millimeter Standard Deviation 31.20	48.31 Millimeter Standard Deviation 29.28	45.40 Millimeter Standard Deviation 29.33

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms) post initiation of TNFis, during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years); data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

Participants assessed their fatigue using a 0 to 100 mm VAS scale, where 0 mm = no fatigue and 100 mm = worst possible fatigue. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=536 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=536 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=670 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=670 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Fatigue VAS at Month 6 and 12: TNFi Monotherapy Versus TNFi Combination Therapy	46.20 Millimeter Standard Deviation 29.80	46.52 Millimeter Standard Deviation 30.31	46.25 Millimeter Standard Deviation 30.88	44.79 Millimeter Standard Deviation 29.48

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

Participants assessed their fatigue using a 0 to 100 mm VAS scale, where 0 mm = no fatigue and 100 mm = worst possible fatigue. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=246 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=246 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=343 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=343 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Fatigue VAS at Month 6 and 12: Tofacitinib Monotherapy Versus TNFi Combination Therapy	48.90 Millimeter Standard Deviation 29.51	47.01 Millimeter Standard Deviation 30.62	47.11 Millimeter Standard Deviation 29.08	48.74 Millimeter Standard Deviation 28.89

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

Participants assessed their fatigue using a 0 to 100 mm VAS scale, where 0 mm = no fatigue and 100 mm = worst possible fatigue. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=344 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=344 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=443 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=443 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Fatigue VAS at Month 6 and 12: Tofacitinib Combination Therapy Versus TNFi Combination Therapy	46.75 Millimeter Standard Deviation 31.10	47.62 Millimeter Standard Deviation 30.17	45.06 Millimeter Standard Deviation 29.00	48.02 Millimeter Standard Deviation 29.41

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

Duration of morning stiffness was defined as the time elapsed when participant woke up in the morning and was able to resume normal activities without stiffness in hours. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=611 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=611 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=735 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=735 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Morning Stiffness Duration at Month 6 and 12: Tofacitinib Overall Versus TNFi Overall	1.39 Hours Standard Deviation 2.96	1.51 Hours Standard Deviation 3.26	1.39 Hours Standard Deviation 2.73	1.56 Hours Standard Deviation 3.07

SECONDARY outcome

Timeframe: Months 6 and 12 visit (for respective arms) post initiation of Tofacitinib during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years); data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

Duration of morning stiffness was defined as the time elapsed when participant woke up in the morning and was able to resume normal activities without stiffness in hours. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=277 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=277 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=345 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=345 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Morning Stiffness Duration at Month 6 and 12: Tofacitinib Monotherapy Versus Tofacitinib Combination Therapy	1.62 Hours Standard Deviation 3.24	1.41 Hours Standard Deviation 3.05	1.38 Hours Standard Deviation 2.60	1.48 Hours Standard Deviation 2.99

SECONDARY outcome

Timeframe: Months 6 and 12 visit (for respective arms) post initiation of TNFis during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years); data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

Duration of morning stiffness was defined as the time elapsed when participant woke up in the morning and was able to resume normal activities without stiffness in hours. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=670 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=670 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=670 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=670 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Morning Stiffness Duration at Month 6 and 12: TNFi Monotherapy Versus TNFi Combination Therapy	1.49 Hours Standard Deviation 3.30	1.48 Hours Standard Deviation 2.95	1.51 Hours Standard Deviation 3.12	1.41 Hours Standard Deviation 2.74

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

Duration of morning stiffness was defined as the time elapsed when participant woke up in the morning and was able to resume normal activities without stiffness in hours. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=246 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=246 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=343 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=343 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Morning Stiffness Duration at Month 6 and 12: Tofacitinib Monotherapy Versus TNFi Combination Therapy	1.51 Hours Standard Deviation 3.08	1.53 Hours Standard Deviation 3.39	1.29 Hours Standard Deviation 2.30	1.28 Hours Standard Deviation 2.38

SECONDARY outcome

Timeframe: Months 6 and 12 visit(for respective arms)post initiation of Tofacitinib or TNFis,during observation period from 06-November-2012 to 28-Feb-2021(approximately 8.3 years);data was collected and studied from 22-January-2021 to 29-November-2021 in this study

Population: Eligible participants whose data were observed in this study. Here for this outcome measure analysis, "Overall Number of Participants Analyzed" refers to evaluable participants who were matched using propensity score method for respective reporting arms.

Duration of morning stiffness was defined as the time elapsed when participant woke up in the morning and was able to resume normal activities without stiffness in hours. Propensity score method was used for analysis of the outcome measure.

Outcome measures

Outcome measures
Measure	Tofacitinib Combination Therapy (12-Month Follow-up) n=344 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as combination therapy with csDMARDs after 06-November-2012 and had at least 12- month follow-up post initiation, were included in this reporting arm.	TNFis Combination Therapy (12-Month Follow-up) n=344 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as combination therapy with csDMARDs after 06-November-2012 and had at least 12-month follow-up post initiation, were included in this reporting arm.	Tofacitinib Overall (6-Month Follow-up) n=443 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated tofacitinib as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6- month follow-up post initiation, were included in this reporting arm.	TNFis Overall (6-Month Follow-up) n=443 Participants Participants diagnosed with RA, enrolled in Coronna RA registry who initiated TNFis (adalimumab, etanercept, infliximab, golimumab, or certolizumab pegol) as monotherapy or combination therapy with csDMARDs after 06-November-2012 and had at least 6-month follow-up post initiation, were included in this reporting arm.
Morning Stiffness Duration at Month 6 and 12: Tofacitinib Combination Therapy Versus TNFi Combination Therapy	1.39 Hours Standard Deviation 3.06	1.62 Hours Standard Deviation 3.46	1.41 Hours Standard Deviation 2.69	1.46 Hours Standard Deviation 2.95

Adverse Events

Tofacitinib (6 Month Follow-up)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

TNFis (6 Month Follow-up)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Tofacitinib (12 Month Follow-up)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

TNFis (12 Month Follow-up)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Pfizer ClinicalTrials.gov Call Center

Pfizer Inc.

Phone: 1-800-718-1021

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
Publication restrictions are in place

Restriction type: OTHER